Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis

Digestive Diseases and Sciences

Volumn 50, Issue 3, 2005, Pages 547-551

  Mohamadnejad, Mehdi ^a,b   Malekzadeh, Reza ^b,c   Nasseri Moghaddam, Siavosh ^b   Hagh Azali, Sepideh ^b   Rakhshani, Nasser ^b   Tavangar, Seyed Mohamad ^b   Sedaghat, Mojtaba ^b   Alimohamadi, Seyed Meysam ^b  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Autoimmune hepatitis; Immunosuppressive agents; Liver fibrosis; Therapeutics

Indexed keywords

ALANINE AMINOTRANSFERASE; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE;

ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LOW DRUG DOSE; MALE; PREDICTION; PRIORITY JOURNAL; REMISSION; THROMBOCYTE;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; CHILD; COHORT STUDIES; CYCLOSPORINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LOGISTIC MODELS; MALE; PREDNISOLONE; PROBABILITY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 17444393210     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-2472-5     Document Type: Article

References (12)

1. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J: Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 32:1131-1137, 2000
2. Hammel P, Couvelard A, O'Toole D, Ratouis A, Sauvanet A, Flejou JF, Degott C, Belghiti J, Bernades P, Valla D, Ruszniewski P, Levy P: Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 344:418-423, 2001
3. Czaja AJ, Carpenter HA: Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 40:646-652, 2004
4. Dufour JF, DeLellis R, Kaplan MM: Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 127:981-985, 1997
5. Cotler SJ, Jakate S, Jensen DM: Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin Gastroenterol 32:428-430, 2001
6. Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, Taheri H, Kamalian N, Sotoudeh M: Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 46:1321-1327, 2001
7. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, Phillips MJ, Portmann BG, Poulsen H, Scheuer PJ, Schmid M, Thaler H: Histological grading and staging of chronic hepatitis. J Hepatol 22:696-699, 1995
8. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38:518-526, 2003
9. Czaja AJ: Autoimmune hepatitis. In Gastrointestinal and Liver Disease, 7th ed. Feldman M, Friedman LS, Sleizenger MH (eds). Philadelphia, Saunders, 2002, pp 1462-1473
10. Marzano A, Trapani A, Leone N, Actis GC, Rizzetto M: Treatment of idiopathic retroperitoneal fibrosis using cyclosporine A. Ann Rheum Dis 60:427-428, 2001
11. Filaci G, Cutolo M, Basso M, Murdaca G, Derchi L, Gianrossi R, Ropolo F, Zentilin P, Sulli A, Puppo F, Indiveri F: Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. Rheumatology (Oxford) 40:1431-1432, 2001
12. Rosenberg WM: Rating fibrosis progression in chronic liver diseases. J Hepatol 38:357-360, 2003